PHILADELPHIA, PA, iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced the completion of a $65 million Series A-1 financing.

The Series A-1 financing was co-led by Novo Holdings A/S and LYFE Capital with significant participation from existing investors Versant Ventures and OrbiMed Advisors.

This financing, coupled with the $50 million raised in the prior Series A financing announced in September 2021, will bring the company's total funds raised to $115 million.